About Us – NovoCell: Innovating Health, Transforming Lives
Welcome to NovoCell, where science meets innovation to redefine the future of health and wellness. Our journey began in 1999 as pioneers in regenerative medicine, dedicated to using cutting-edge stem cell technologies to combat chronic conditions like diabetes. Today, with decades of expertise, relentless research, and a passion for improving lives, we have expanded our mission to include groundbreaking solutions for human growth and development.
The Early Days: A Vision for Regenerative Medicine
NovoCell started with a bold vision: to harness the transformative power of stem cells to create therapies that could revolutionize the treatment of chronic diseases. By merging with CyThera and BresaGen in 2004, we formed a robust foundation for innovation, solidifying our position as leaders in stem cell-based therapies.
Our commitment to combating the diabetes epidemic was evident in the development of our flagship therapy, VC-01™, which introduced a highly engineered cell product for replacing lost pancreatic functions in patients with diabetes. Through partnerships with leading organizations, including the California Institute of Regenerative Medicine and Pfizer, we achieved remarkable breakthroughs, including the first functional human islet cells published in vivo in 2007.
A Turning Point: Expanding Our Mission
By 2010, we had firmly established ourselves as pioneers in cell-based therapies, delivering hope to millions battling diabetes. But we knew our expertise in cellular engineering and regenerative science had broader potential. In 2025, NovoCell took an ambitious leap forward, entering the field of Human Growth Hormone (HGH) therapies.
Why HGH?
The decision to include HGH products in our portfolio was driven by a deep understanding of the growing need for safe and effective solutions to support health, vitality, and longevity. Human Growth Hormone (HGH) therapy offers transformative benefits for individuals seeking to address age-related challenges, enhance recovery, or improve physical performance. Recognizing this potential, NovoCell embraced the role of a trusted partner in scientific research, consultation, and the legal distribution of HGH products from reliable manufacturers.
NovoCell HGH Solutions: Where Science Meets Integrity
At NovoCell, we do not produce HGH products ourselves. Instead, we are dedicated to leveraging our expertise in regenerative medicine to ensure that customers have access to high-quality products from reputable and verified manufacturers. Through rigorous research and collaboration, we help connect individuals with HGH solutions that are safe, effective, and fully compliant with legal and regulatory standards.
- Research-Driven Insights: Our team is engaged in cutting-edge research to explore the benefits and applications of HGH therapies, ensuring our recommendations are grounded in science.
- Reliable Partnerships: We work only with trusted manufacturers who meet the highest quality and safety standards, offering customers peace of mind.
- Customer Support and Education: NovoCell provides expert consultation to guide customers on their journey, ensuring they make informed decisions about their health.
By focusing on research, consultation, and the legal distribution of trusted HGH products, NovoCell continues to empower individuals to take charge of their health and achieve their wellness goals with confidence.
Our Management
Fred A. Middleton, Chairman of the Board
Fred Middleton brings over 30 years of expertise in biotechnology and biomedical industries, spanning corporate operations and institutional venture capital.
As Managing Director at Sanderling Ventures since 1988, he has contributed to the growth of more than 25 biomedical ventures as an investor, board member, and management team member.
Previously, Mr. Middleton served as the founding CFO and VP of Corporate Development at Genentech, where he played a key role in shaping the company’s early success.
He holds a B.S. in Chemistry from MIT and an M.B.A. with distinction from Harvard Business School. Mr. Middleton also serves as a member of the MIT Corporation (Board of Trustees).
Mark G. Foletta, CPA, Director
Mark Foletta has deep expertise in finance and auditing, particularly in the biotechnology and pharmaceutical sectors.
He served as Senior VP of Finance and CFO at Amylin Pharmaceuticals from 2006 until its acquisition by Bristol-Myers Squibb in 2012.
Earlier roles included leadership positions at Intermark, Triton Group, and Ernst & Young. He has also served on boards including AMN Healthcare Services and Regulus Therapeutics.
Mr. Foletta earned a B.A. in Business Economics from UC Santa Barbara, is a Certified Public Accountant, and is a member of the Financial Executives Institute.
Orville G. Kolterman, M.D., Director
Dr. Orville Kolterman is a leading expert in diabetes medicine with a 20-year tenure at Amylin Pharmaceuticals, where he played a pivotal role in developing groundbreaking diabetes treatments, including SYMLIN and BYETTA.
In addition to his clinical and research contributions, Dr. Kolterman has been actively involved in advancing industry standards for diabetes care through leadership roles with the American Diabetes Association.
An Adjunct Professor of Medicine at UC San Diego for over 20 years, Dr. Kolterman earned his medical degree from Stanford University School of Medicine.
Paul K. Laikind, Ph.D., President, CEO, and Director
Dr. Paul Laikind has over 28 years of leadership experience in the biotech and life sciences industries.
A serial entrepreneur, he co-founded three companies—Gensia Pharmaceuticals, Viagene, and Metabasis Therapeutics—all of which went public before being acquired.
Currently, Dr. Laikind serves as President and CEO of ViaCyte, a leader in regenerative medicine. He holds a B.S. in Biochemistry from UC Davis and a Ph.D. in Biochemistry from UC San Diego.
Dr. Laikind is also a board member and past Chairman of BIOCOM and Chairman Emeritus of CONNECT.